7.33
Emergent Biosolutions Inc stock is traded at $7.33, with a volume of 634.63K.
It is up +0.96% in the last 24 hours and down -14.07% over the past month.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
See More
Previous Close:
$7.26
Open:
$7.36
24h Volume:
634.63K
Relative Volume:
0.78
Market Cap:
$378.20M
Revenue:
$676.80M
Net Income/Loss:
$-8.60M
P/E Ratio:
-25.91
EPS:
-0.2829
Net Cash Flow:
$135.40M
1W Performance:
-4.68%
1M Performance:
-14.07%
6M Performance:
-40.02%
1Y Performance:
+2.23%
Emergent Biosolutions Inc Stock (EBS) Company Profile
Name
Emergent Biosolutions Inc
Sector
Phone
240-631-3200
Address
300 PROFESSIONAL DR, GAITHERSBURG, MD
Compare EBS vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
EBS
Emergent Biosolutions Inc
|
7.33 | 374.59M | 676.80M | -8.60M | 135.40M | -0.2829 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.44 | 55.06B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
HLN
Haleon Plc Adr
|
9.94 | 43.07B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.08 | 35.88B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
ZTS
Zoetis Inc
|
76.92 | 31.59B | 9.51B | 2.64B | 2.14B | 6.0361 |
|
UTHR
United Therapeutics Corp
|
527.94 | 26.32B | 3.17B | 1.29B | 1.01B | 27.09 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-07-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-20-23 | Resumed | JP Morgan | Underweight |
| Aug-29-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Apr-10-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-10-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Apr-29-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-20-22 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-08-21 | Downgrade | The Benchmark Company | Buy → Hold |
| May-05-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Initiated | The Benchmark Company | Buy |
| Feb-24-21 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-19-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jan-08-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Jul-31-20 | Reiterated | Chardan Capital Markets | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| Sep-04-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-02-18 | Upgrade | Goldman | Neutral → Buy |
| Aug-03-18 | Reiterated | Chardan Capital Markets | Buy |
| Jun-13-18 | Initiated | Argus | Buy |
| Apr-25-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Jan-16-18 | Reiterated | Chardan Capital Markets | Buy |
| Jun-28-16 | Reiterated | Singular Research | Buy |
| Apr-15-16 | Initiated | Chardan Capital Markets | Buy |
| Mar-28-16 | Initiated | Singular Research | Buy |
| Feb-19-16 | Initiated | Wells Fargo | Outperform |
| May-15-14 | Initiated | Summer Street Research | Buy |
| May-31-11 | Reiterated | WBB Securities | Strong Buy |
| Jan-10-11 | Reiterated | Wedbush | Outperform |
| Nov-05-10 | Reiterated | Wedbush | Outperform |
| Aug-18-10 | Upgrade | WBB Securities | Buy → Strong Buy |
| Aug-06-10 | Reiterated | Caris & Company | Buy |
View All
Emergent Biosolutions Inc Stock (EBS) Latest News
Emergent BioSolutions Inc (EBS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
EBS|Emergent BioSolutions Inc|Price:7.260| - TradingKey
EBS|Emergent BioSolutions Inc|Price:7.260|Chg%:-0.240 - TradingKey
EBS5025997 Bond Risk Profile - TradingView
EBS5025997 Bond Profile — Key Metrics - TradingView
Emergent BioSolutions Inc (EBS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Emergent BioSolutions to report Q2 2026 results on August 5 - scanx.trade
Emergent BioSolutions to Report Second Quarter 2026 Financial Results on August 5, 2026 - The Manila Times
Emergent BioSolutions offers live webcast for Aug. 5 results call - Stock Titan
Emergent BioSolutions (EBS) AGM 2026 Summary - Quartr
Emergent BioSolutions (EBS) Q3 2024 earnings summary - Quartr
Emergent BioSolutions (EBS) Proxy filing Summary - Quartr
Emergent BioSolutions (EBS) Q1 2026 earnings summary - Quartr
Lobbying Update: $510,000 of EMERGENT BIOSOLUTIONS INC lobbying was just disclosed - Quiver Quantitative
EBS5025998 Bond Profile — Key Metrics - TradingView
EBS5025998 Bond Coupon Profile — Rate & Payments - TradingView
Price to sales forward of Emergent BioSolutions Inc. – LS:A0LC2W - TradingView
Why Did Emergent Biosolutions Stock Tumble 20% After-Hours Today? - Stocktwits
Emergent BioSolutions Inc. (NYSE:EBS) Shares Sold by Mutual of America Capital Management LLC - 富途牛牛
Emergent BioSolutions Company Profile & Introduction - Moomoo
Emergent BioSolutions highlights its role in specialty vaccines as investors weigh the long-term out - Ad-hoc-news.de
Insider Sell: Paul Williams Sells 3,000 Shares of Emergent BioSo - GuruFocus
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Officer Williams Paul Anthony - Moomoo
Emergent BioSolutions SVP Williams sells $25,200 in common stock By Investing.com - Investing.com Nigeria
Emergent BioSolutions SVP Williams sells $25,200 in common stock - Investing.com
Form 4 Emergent Biosolutions Inc For: 2 July By Investing.com - Investing.com Canada
Emergent BioSolutions (EBS) SVP sells 3,000 shares under plan - Stock Titan
Emergent BioSolutions | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
[144] Emergent BioSolutions Inc. SEC Filing - Stock Titan
Emergent BioSolutions Secures Contract Modification Valued At Approximately USD 52.7 Million From The United States Department Of Health And Human Services To Supply ACAM2000 - marketscreener.com
Emergent BioSolutions Secures New ACAM2000 Biodefense Contract - TipRanks
Emergent BioSolutions (NYSE: EBS) lands $52.7M U.S. ACAM2000 contract - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Emergent BioSolutions (EBS) Secures $52.7M Contract for Smallpox Vaccine Supply - GuruFocus
Emergent BioSolutions wins $52.7m smallpox vaccine contract By Investing.com - Investing.com South Africa
Emergent BioSolutions wins $52.7m smallpox vaccine contract - Investing.com
U.S. government adds $52.7M ACAM2000 order for smallpox preparedness - Stock Titan
Emergent BioSolutions Inc. Actuals & Estimates (NYSE:EBS) - TradingView
Emergent BioSolutions | 8-K: Current report - Moomoo
Emergent BioSolutions Inc. Actuals & Estimates (BOATS:EBS) - TradingView
EBS Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of Emergent BioSolutions Inc. – NYSE:EBS - TradingView
Enterprise value to revenue forward of Emergent BioSolutions Inc. – BOATS:EBS - TradingView
Price to sales forward of Emergent BioSolutions Inc. – NYSE:EBS - TradingView
Emergent Biosolutions studies intranasal naloxone for opioid overdose response - Traders Union
Emergent BioSolutions Inc (EBS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Emergent BioSolutions Inc (EBS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Emergent BioSolutions StockSunday background on the business and risk profile - AD HOC NEWS
Why Emergent’s Narcan nasal spray is becoming a quiet everyday life saver - Ad-hoc-news.de
Emergent BioSolutions Inc (EBS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Emergent Biosolutions Inc Stock (EBS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):